FAQ

denileukin diftitox/dexamethasone

Known as: DAB389-IL2/DM 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2009
01220022009

Related topics

Related topics

2 relations
Dexamethasonedenileukin diftitox

Related mentions per year

Related mentions per year

1949-2018
19401960198020002020
denileukin diftitox/dexamethasone
Dexamethasone
denileukin diftitox

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer.
INTRODUCTION Denileukin diftitox, a chimeric protein, uses the cytocidal properties of diphtheria toxin to cells expressing… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
CD4+CD25+Foxp3+ regulatory T (Treg) cells have been implicated in the lack of effective antitumor immunity. Denileukin diftitox… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2007
2007
Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.
 
Is this relevant?
2006
2006
Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
BACKGROUND Denileukin diftitox, a fusion protein consisting of peptide sequences for the enzymatically active and membrane… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Elimination of regulatory T lymphocytes may provide a way to break self-tolerance and unleash the anti-tumor properties of… (More)
Is this relevant?
2002
2002
Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions. As part of a multicenter… (More)
Is this relevant?